Radiopharma has spent the past several years racing to acquire drug candidates, targeting platforms, isotopes and manufacturing capacity. The next land grab is taking place closer to the patient, where radioactive products must move through a tightly coordinated network of radiopharmacies, couriers, hospitals and treatment centers before they can generate revenue.
GE HealthCare is reportedly discussing a transaction to acquire Sofie Biosciences for approximately $1 billion, although neither company has announced an agreement. The potential deal would give GE more than a portfolio of PET imaging agents because Sofie also operates a distributed network of radiopharmacies capable of producing and delivering short-lived products near the hospitals and imaging centers that use them.
That network may be the most strategically important part of the transaction. Developing a radiopharmaceutical is difficult, but getting a time-sensitive radioactive product from a manufacturing site into a patient at the correct activity and appointment time is an entirely different challenge.
Traditional pharmaceutical companies can manufacture many drugs centrally, place them into inventory and distribute them through national wholesalers. Radiopharmaceuticals operate under a different commercial model because the product begins losing usable activity as soon as it is made, turning geography into part of the product itself.
Manufacturing location, release timing, flight schedules, road networks, courier availability and the distance between a radiopharmacy and a hospital can determine whether a dose reaches its patient. For fluorine-18 products, which have a physical half-life of approximately 110 minutes, a delay at the production site, a quality-control problem, a missed flight or traffic between the radiopharmacy and imaging center can reduce the available activity and disrupt an entire patient schedule.
Even longer-lived therapeutic isotopes do not eliminate the last-mile problem. Radiopharmaceutical therapies still require tightly coordinated manufacturing, patient scheduling, specialized packaging, regulatory documentation and delivery to licensed treatment centers prepared to receive and administer radioactive material.
The company that owns the molecule therefore does not necessarily own the complete patient experience. Between an approved product and an administered dose sits a network of manufacturers, radiopharmacies, logistics providers, hospitals and clinical teams that must perform correctly every time.
Telix Pharmaceuticals made its move into the last mile through its $230 million acquisition of RLS Radiopharmacies, a transaction that gave the company a network of 31 licensed radiopharmacies across the United States. The acquisition added local production and distribution infrastructure to a business already built around radiopharmaceutical diagnostics and therapeutics.
RLS provides Telix with more than delivery capacity. The network creates direct relationships with hospitals and imaging centers, offers a platform for distributing Telix products and gives the company physical infrastructure that could support additional diagnostic and therapeutic radiopharmaceuticals.
That vertical integration also reduces Telix’s dependence on third parties for an important part of commercialization. Instead of treating the radiopharmacy as an outside vendor at the end of the supply chain, Telix can connect product planning, manufacturing, distribution and customer support through a network it controls.
Telix’s move showed that a radiopharmacy network can be more than a service business with local delivery routes. In the hands of a radiopharmaceutical developer, it can become a commercial platform capable of supporting an expanding portfolio and bringing the company closer to the sites where patients are diagnosed and treated.
Other transactions reinforce the same pattern. Lantheus added development and manufacturing capabilities through its acquisition of Evergreen Theragnostics, while Curium has now agreed to acquire Lantheus in a transaction valued at up to $8 billion.
If the reported GE-Sofie talks also produce a deal, another major imaging company would be strengthening its position through a business that combines radiopharmaceutical products with the infrastructure required to manufacture and distribute them. These are not simply portfolio transactions; they reflect a broader recognition that radiopharmaceutical commercialization depends on control over a fragmented and operationally demanding delivery system.
A distributed radiopharmacy network can support existing imaging agents, provide a launch platform for new tracers and create direct relationships with hospitals and imaging centers. It can also give its owner visibility into ordering patterns, customer demand, regional capacity and the operational problems that determine whether a product succeeds after approval.
Those relationships are difficult to reproduce quickly. A competitor can license another molecule or construct a facility, but building a dependable network of local production sites, customer contracts, regulatory licenses and experienced personnel takes years.
Clinical performance and regulatory approval remain essential, but they do not guarantee commercial adoption. Physicians may want to use a new imaging agent or therapy and still be unable to order it reliably, schedule patients efficiently or justify changing established workflows.
That creates an advantage for companies that can place a new product into an existing distribution system. A radiopharmacy already serving an imaging center has customer relationships, delivery routes, ordering processes and knowledge of local demand, reducing the friction involved in launching another tracer.
The same infrastructure can also protect established products because when two radiopharmaceuticals offer comparable clinical value, customers may favor the one backed by more reliable supply, easier ordering and stronger local support. This is why the last mile should not be treated as a commodity service performed after the important work has been completed; in radiopharma, distribution is part of the product’s clinical reliability and commercial value.
Owning more of the supply chain can improve coordination, reduce dependence on outside suppliers and make it easier to introduce new products. It can also create conflicts when a radiopharmacy network owned by one manufacturer is asked to produce or distribute a competitor’s radiopharmaceutical.
An independent network can position itself as neutral infrastructure serving multiple developers. Once it is acquired by a company with its own portfolio, customers and competitors may begin asking whether their products will receive the same priority, commercial terms and operational support.
Market concentration could make those questions more important. If a small number of companies control major diagnostic products, radiopharmacy networks and customer relationships, emerging developers may find that market access depends on partnering with one of their largest competitors.
Regulators may also need to consider the market differently. A transaction involving two drug portfolios can be evaluated through product overlap, but a vertically integrated radiopharmaceutical company may exercise influence through manufacturing slots, geographic coverage, distribution capacity and customer access even when the underlying molecules do not compete directly.
Consolidation could create an opening for independent radiopharmacies, contract manufacturers and logistics providers that can offer developers a neutral route to market. Companies without their own networks will need partners capable of supporting clinical trials and commercial launches without favoring an affiliated portfolio.
That independence will only be valuable if it is accompanied by scale and reliability. A collection of isolated sites is not the same as a coordinated network with consistent quality systems, validated processes, scheduling technology and national customer support.
The next generation of infrastructure companies may therefore be built around interoperability as much as ownership. Developers will need networks that can accept products from multiple manufacturing platforms, move them through different regional channels and give customers a consistent ordering experience.
Digital systems will also become part of that infrastructure. The industry needs better visibility into production schedules, available activity, patient appointments, courier movements, disruptions and unused capacity so that supply can be coordinated before doses are lost to decay.
Radiopharmaceutical companies have spent billions of dollars acquiring promising targets and therapeutic platforms. They are now discovering that the value of those assets depends on whether they can manufacture, distribute and administer the resulting products at commercial scale.
Telix’s acquisition of RLS demonstrated how a radiopharmacy network can become part of a broader radiopharmaceutical strategy. The reported GE-Sofie talks make sense in the same context because GE already understands imaging equipment and pharmaceutical diagnostics, while Sofie would add products, local production and a direct route into PET imaging centers.
Whether that particular transaction is completed or not, the direction of the market is becoming clearer. Companies are moving beyond owning individual radiopharmaceuticals and toward controlling the systems through which those products reach patients.
The next radiopharma winners will still need differentiated science, strong clinical evidence and dependable isotope supply, but they will also need command of the final miles. In an industry where every minute consumes part of the product, distribution is not what happens after commercialization; it is commercialization.
